Why the study?
Does the ACS RX flow support catheter improve outcomes in patients with suboptimal percutaneous interventional results?
Does the ACS RX flow support catheter improve outcomes in patients with suboptimal percutaneous interventional results?
Answers are grounded in this paper and cite their sources.
The ACS RX flow support catheter shows promise in improving coronary flow and reducing stenosis after suboptimal PCI, but safety concerns regarding major complications remain.
Although permanent stents have been successfully used as bail-out devices in the treatment of abrupt occlusion, the risk of stent thrombosis and of bleeding complications, as well as the cost of a prolonged hospitalization, have been deterrents to their universal acceptance. Temporary stents were conceived to provide internal scaffolding of the coronary arteries, which could stabilize occlusive dissections, yet still allow the stent to be removed before the time of peak incidence of subacute thrombosis. The ACS RX flow support catheter is a prototype temporary stent which has been recently evaluated in phase I and II clinical trials. The device is effective in improving angina score, coronary flow, and decreasing residual stenosis when used in cases of suboptimal percutaneous interventional results. However, the incidence of major complications and the need for adjunctive percutaneous interventions remain significant. Further studies are needed to define the optimal time of cage expansion as well as the clinical, anatomical, and procedural factors that predict efficacy and safety of this new device.
No takes yet. Share an insight, caveat, or question.
Abdelmeguid et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: